Anton Pampols, PaulaTrujillo, HernandoMelilli, EdoardoUrban, BlancaSandino, JustoFavà Buch, AlexandreGutierrez, EduardoBestard Matamoros, OriolMancebo, EstherSevillano, AngelCruzado, Josep Ma.Morales, Enrique2021-05-282021-05-282021-01-29https://hdl.handle.net/2445/177731Background. Immunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during COVID-19 must be characterized. Methods. Herein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units, who survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and immunologic events was evaluated. Results. At least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent. Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19. Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes or de novo donorspecific antibodies were observed up to 3 months after discharge, and no significant changes occurred in calculated panel reactive antibodies. Acute graft dysfunction was common (55%) and the severity was related to tacrolimus trough levels, which were higher in patients receiving antivirals. At the end of follow-up, all patients recovered baseline kidney function. Conclusions. Our observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely minimized.7 p.application/pdfengcc by-nc (c) Anton Pampols et al., 2021http://creativecommons.org/licenses/by-nc/3.0/es/ImmunosupressorsCOVID-19Trasplantament renalImmunosupressive agentsCOVID-19Kidney transplantationinfo:eu-repo/semantics/article2021-05-27info:eu-repo/semantics/openAccess